In one breath
Eli Lilly’s Q2 2026 10-Q confirms revenue nearly doubling in two years, with two weight-loss drugs now generating almost two-thirds of every dollar the company earns. The stock trades at roughly half its own decade-median earnings multiple, meaning the market is pricing in a slowdown that the filed numbers have not yet shown. The open question is whether the pricing pressure management quietly disclosed on the call is a temporary friction or the first crack in the franchise.
What arrived, and the sentence that matters
On August 5, 2026, Eli Lilly filed its 10-Q for the quarter ended June 30, 2026 and held its earnings call the same morning. The sentence that matters sits in the revenue line: $23.0 billion for a single quarter, up 48% from the same period a year earlier. To feel the scale, consider that Lilly’s entire annual revenue as recently as 2022 was $28.5 billion, per the FY2023 10-K. A single quarter now delivers revenue approaching what the entire company earned in a full year just four years ago.
That context matters because Lilly has a complicated recent history with its own forward statements. In early 2025, the company cut its full-year 2024 revenue forecast by a meaningful margin, blaming unexpected stocking dynamics in the GLP-1 market. Then Q1 2025 EPS missed analyst forecasts outright. Investors who remember those stumbles are reading this call with a sharper pencil than usual.
Claim one: “Momentum continues”
What was said. CEO David Ricks told the call that the company’s “momentum continues,” pointing to the GLP-1 franchise as the engine. Management cited a majority of the global GLP-1 market and six of every ten obesity prescriptions written in the U.S., according to the Q2 2026 earnings call transcript.
What the filing votes. The 10-Q confirms Mounjaro and Zepbound together account for roughly 64% of Q2 revenue, with both products growing sharply year-over-year. Market-share data from Becker’s Hospital Review puts Lilly’s U.S. GLP-1 share at 54.8% as of late July 2026, up from 47% a year earlier, while Novo Nordisk’s injectable Wegovy sales fell in the same quarter despite the launch of an oral version.
Verdict: holds. The market-share claim is corroborated by third-party data, and the revenue trajectory in the filing matches the tone of the call. The momentum claim is not spin; it is arithmetic.
Claim two: the guidance raise
What was said. Management raised full-year 2026 revenue guidance to a range of $85 billion to $87 billion, up from the prior range set after Q1, and updated non-GAAP EPS guidance to a new band, according to Pharmaceutical Technology.
What the filing votes. The math is straightforward. Q2 alone delivered $23.0 billion. The full-year 10-K for 2025 shows $65.2 billion in annual revenue, meaning the new guidance midpoint implies roughly a third more revenue for the full year, consistent with the pace already filed. Analyst consensus as of early August sat inside the lower half of the company’s own range, per MarketBeat.
Verdict: holds, with one asterisk. The EPS guidance ceiling was trimmed modestly because of per-share charges taken in Q2 for acquired in-process research and development. These charges represent money spent on drug programs acquired before they reach market and are real cash out the door even if excluded from the non-GAAP headline. The call presented the EPS revision as a mechanical adjustment; the filing confirms that framing is accurate.
Claim three: pricing is fine
What was said. This is where the ledger gets interesting. Management’s prepared remarks emphasized volume as the growth driver, which is true. But buried in the call, the company disclosed that underlying U.S. net pricing for its GLP-1 drugs declined approximately 9% in Q2, excluding one-time adjustments, according to Pharm Exec.
What the filing votes. The 10-Q confirms the revenue figures but does not contradict the pricing disclosure. The growth story is entirely a volume story: more patients, more prescriptions, more vials shipped. Price per unit is moving the other way. That is not a crisis at current volumes, but it is a structural fact that the call’s optimistic framing did not lead with.
Verdict: technically accurate, selectively framed. Nothing management said was false. But a listener who absorbed only the headline claims would not know that the company is growing through volume while giving back price. For a business whose long-term margin depends partly on what insurers and pharmacy benefit managers will pay, that price erosion is worth tracking quarter by quarter.
Claim four: the pipeline is real
What was said. Management highlighted positive Phase 3 results for retatrutide, its next-generation weight-loss candidate, with a Biologics License Application planned for Q1 2027. The oral GLP-1 Foundayo, launched in April 2026, was described as “doubling total prescriptions in the last month of Q2.”
What the filing votes. The 10-Q confirms the retatrutide Phase 3 package is complete and the BLA filing timeline. Foundayo generated $98 million in Q2, its first full quarter, a small number relative to the injectable franchise but a real one. The FiercePharma oral GLP-1 tracker shows Novo Nordisk’s oral Wegovy has exceeded five million U.S. prescriptions since its January 2026 launch, meaning the oral segment is competitive from day one. Lilly’s claim of doubling prescriptions is a rate-of-change statement, not a scale statement, and the filing does not contradict it.
Verdict: holds, with competitive context the call underplayed. The pipeline claims are grounded. What the call did not dwell on is that Novo’s oral entry is already large, and Roche’s competing molecule is in Phase 3 with a potential launch before the end of the decade, per Global News. Lilly’s lead is real; it is not permanent by default.
Reading the numbers
- Q2 2026 revenue: $23.0 billion, up 48%. This means the company added roughly $7.5 billion of quarterly revenue in a single year, more than most pharmaceutical companies earn in a full year. Source: 10-Q filed August 2026. A household analogy: if a family’s income grew at this rate, a $100,000 salary would become $148,000 in twelve months.
- Mounjaro + Zepbound combined: $14.9 billion in Q2. That is 64 cents of every dollar Lilly earned in the quarter. Two products. One mechanism (GLP-1/GIP receptor activation, meaning they mimic gut hormones that regulate appetite and blood sugar). Source: PR Newswire earnings release.
- FY2025 net margin: 31.7%. For every dollar of sales, Lilly kept about 32 cents as profit after all costs, per our data computed from the FY2025 10-K. In 2023 that figure was 15.4%, meaning profitability has more than doubled in two years. A restaurant earning 5% margins would consider 32% a different business entirely.
- Valuation vs. growth. The math (what filed fundamentals justify) and the mood (what the market is currently paying) are unusually inverted for a growth company. That gap is the story the price is telling.
- U.S. net price decline of approximately 9% in Q2. If a drug that cost an insurer $100 last year now costs roughly $91, volume must grow faster than 9% just to hold revenue flat. At current growth rates that math works easily. The question is what happens if volume growth moderates. Source: Pharm Exec.
The overall ledger reads mostly clean. Management’s headline claims held up against the filed record. The one place the call and the filing diverge in emphasis, not in fact, is pricing. Volume is carrying the business today. Whether it carries it at the same pace in 2027 is the question the filing cannot yet answer, and the one the market appears to be pricing with some skepticism.
Sources
- Eli Lilly 10-Q, quarter ended June 30, 2026 (SEC EDGAR)
- Eli Lilly 10-K, fiscal year ended December 31, 2025 (SEC EDGAR)
- Eli Lilly 10-K, fiscal year ended December 31, 2023 (SEC EDGAR)
- Lilly Q2 2026 earnings press release (PR Newswire)
- Eli Lilly Q2 2026 earnings call transcript (Seeking Alpha)
- Eli Lilly raises 2026 outlook (Pharmaceutical Technology)
- Eli Lilly FY2026 guidance release (MarketBeat)
- Lilly surpasses estimates, injectable GLP-1 (Pharm Exec)
- Lilly widens GLP-1 lead over Novo (Becker’s Hospital Review)
- Oral GLP-1 tracker (FiercePharma)
- Lilly misses 2024 revenue estimate (Pharmaceutical Technology)
- GLP-1 competitive landscape (Global News)
